Search

Investigating the possibility of combining a medicine that blocks the process with a medicine that triggers a cell's defensive response to treat ALL.

Creating a new immunotherapy that will attacks collagen in cancer cells, and testing whether it is effective in model systems to make it the best it can be.

Investigating how antibody immunotherapy causes pain and nerve damage.

Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.

Investigating a protein found on leukaemia stem cells, the cells which cause relapse, and whether it could be a good drug target.

Using a new way to measure genetic variation in key sections of noncoding DNA.

Finding the biological differences between teenage and young adult cancers cells compared to older adults.

Understanding how the MYCN protein changes the amounts of other proteins in the cell by changing the way DNA is processed and translated.

Leukaemia is a type of blood cancer. Leukaemias are the most common group of childhood cancers, accounting for approximately 1 in 3 cases every year.

Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.